Clinical observation of early re-induction with priming low dose regimen containing G-CSF in treating acute myeloid leukemia
10.3969/j.issn.1671-8348.2017.25.015
- VernacularTitle:含G-CSF预激小剂量方案早期再诱导治疗急性髓系白血病的临床观察
- Author:
Xun NI
;
Xinli ZOU
;
Kunying XIE
;
Wenjun ZHOU
;
Wenfeng LUO
;
Jin WEI
- Keywords:
leukemia;
complete remission;
re-induction;
priming
- From:
Chongqing Medicine
2017;46(25):3500-3502
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the remission situation of early re-induction with priming low dose regimen containing G-CSF in treating acute myeloid leukemia (AML).Methods Ninety-seven AML patients in our hospital from March 2015 to January 2017 were retrospectively analyzed.All cases adopted the standard DA regimen for conducting the induction chemotherapy,among them,38 cases had significant residual disease on 14 d of induction chemotherapy,21 cases adopted the low dose priming regimen for conducting the early re-induction chemotherapy,17 cases adopted the tandard DA gregimen for conducting the re-induction chemotherapy.The complete remission(CR) rate and and adverse reactions were compared between two groups.Results The total CR rate in all 97 cases was 60.8％;among 38 cases needing re-induction chemotherapy,the CR rate in the priming regimen re-induction group was 76.2 ％,which was significantly higher than 41.2 ％ in the DA regimen re-induction group,the difference was statistically significant (P=0.028);the occurrence rates of side effects such as infection and cytopenia during re-induction chemotherapy process had no difference between two groups(P＞0.05).Conclusion For AML patients with obvious residual disease on 14 d of induction chemotherapy,adopting low dose priming regimen in re-duction chemotherapy has higher CR,which is superior to the standard DA regimen.
